Abstract
BackgroundAlthough bevacizumab has deleterious effects on the healing of colonic anastomoses, trapidil improves wound healing of colonic and tracheal anastomoses.ObjectiveWe aimed to assess the effects of bevacizumab and trapidil on wound healing after tracheal transection.Materials and methodsWe evaluated 35 rats divided in 5 groups: bevacizumab (Group I, n = 7), trapidil (Group II, n = 7), trapidil + bevacizumab (Group III, n = 7), controls (Group IV, n = 7), and sham (Group V, n = 7). Anastomotic healing was assessed by measurement of bursting pressure and inflammation score at the anastomotic region on the seventh day.ResultsThe bursting pressures of Group II, Group III, and Group V were significantly higher than controls (P = 0.001, P = 0.033, and P = 0.035, respectively). Fibrosis was significantly high in the sham group when compared with the other four groups (P = 0.047).ConclusionsAlthough bevacizumab seems to impair anastomotic healing, trapidil can be suggested to improve tracheal anastomoses.
Highlights
Bevacizumab has become the standard therapy in a variety of solid tumors, including colorectal, kidney, gliablastome multiforme, and lung cancer.[1,2,3] Many studies have demonstrated deleterious effects of agent targeting vascular endothelial growth factor on the healing of colonic anastomoses
We aimed to investigate the effects of bevacizumab and trapidil on wound healing after tracheal transection
The bursting pressures of Group II, Group III, and Group V were significantly higher than the controls (P 1⁄4 0.001, P 1⁄4 0.033, and P 1⁄4 0.035, respectively)
Summary
Bevacizumab has become the standard therapy in a variety of solid tumors, including colorectal, kidney, gliablastome multiforme, and lung cancer.[1,2,3] Many studies have demonstrated deleterious effects of agent targeting vascular endothelial growth factor on the healing of colonic anastomoses. Vascular endothelial growth factor-targeted therapies inhibit nitric oxide synthetase. By this way the release of nitric oxide will decrease.[3]. Objective: We aimed to assess the effects of bevacizumab and trapidil on wound healing after tracheal transection. Results: The bursting pressures of Group II, Group III, and Group V were significantly higher than controls (P 1⁄4 0.001, P 1⁄4 0.033, and P 1⁄4 0.035, respectively). Conclusions: bevacizumab seems to impair anastomotic healing, trapidil can be suggested to improve tracheal anastomoses
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
